HEC72702

Cat. No.:	HY-123767
CAS No.:	1793063-59-8
Molecular Formula:	$C_{24}H_{26}BrFN_4O_5S$
Molecular Weight:	581.45
Target:	HBV
Pathway:	Anti-infection
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

HEC72702 is a potent and orally active hepatitis B virus capsid inhibitor with an EC_{50} values of 0.039 μM. HEC72702 dose-dependently reduced HBV DNA in both the plasma and livers[1].

IC_{50} & Target

EC_{50}: 0.039 μM (hepatitis B virus capsid)[1]

In Vivo

HEC72702 (50, 100 mg/kg; p.o.; daily for 7 days) dose-dependently reduces HBV DNA in both the plasma and livers copies[1].

Pharmacokinetic Parameters of HEC72702 in Male Sprague-Dawley rats[1].

dose (mg/kg)	iv (2)	po (5)
$AUC_{(0\text{-}24\ h)}$ (h*ng/mL)	4110	4900
CL (mL/min/kg)	8.11	
V_{SS} (L/kg)	0.41	
F %		47.7

Male Sprague-Dawley rats, 2 mg/kg iv; 5 mg/kg po[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-7 weeks, 16-18 g, Female BALB/c mice(HDI mouse model)[1]
Dosage:	50, 100 mg/kg
Administration:	P.o.; daily for 7 days
Result:	Demonstrated a dose-dependent reduction of HBV DNA in the plasma of infected mice.

REFERENCES

[1]. Ren Q, et al. 3-((R)-4-(((R)-6-(2-Bromo-4-fluorophenyl)-5-(ethoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)propanoic Acid (HEC72702), a Novel Hepatitis B Virus Capsid Inhibitor Based on Clinical Candidate GLS4. J Med Chem. 2018 Feb 8;61(3):1355-1374.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA